OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas.
SB27
Biosimilar candidate
- Molecule Pembrolizumab
- Reference Biologic Keytrudai
- Therapeutic Area Oncology
SB33
Biosimilar candidate
- MoleculeDupilumab
- Reference BiologicDupixentii
- Therapeutic AreaImmunology
SB34
Biosimilar candidate
- MoleculeGuselkumab
- Reference BiologicTremfyaiii
- Therapeutic AreaImmunology
SB35
Biosimilar candidate
- MoleculeIxekizumab
- Reference BiologicTaltziv
- Therapeutic AreaImmunology
SB36
Biosimilar candidate
- MoleculeVedolizumab
- Reference BiologicEntyviov
- Therapeutic AreaImmunology
SB37
Biosimilar candidate
- MoleculeOcrelizumab
- Reference BiologicOcrevusvi
- Therapeutic AreaNeurology
SB38
Biosimilar candidate
- MoleculeTrastuzumab
deruxtecan - Reference BiologicEnhertuvii
- Therapeutic AreaOncology
SBE303
Novel biologic
- Therapeutic Area Oncology
(Nectin-4 ADC)
*Pipeline last updated Jan 2026
- i Keytruda is a trademark of Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD
- outside the United States and Canada.
- ii Dupixent is a trademark of Sanofi.
- iii Tremfya is a trademark of Johnson & Johnson.
- iv Taltz is a trademark of Eli Lilly.
- v Entyvio is a trademark of Millennium Pharmaceuticals.
- vi Ocrevus is a trademark of Genentech/Roche.
- vii Enhertu is a trademark of Daiichi Sankyo.
